Skip to main content

Scopus Biopharma, Inc. (SCPS)

NASDAQ: SCPS · IEX Real-Time Price · USD
3.72 -0.05 (-1.25%)
Oct 26, 2021 11:43 AM EDT - Market open
Market Cap67.31M
Revenue (ttm)n/a
Net Income (ttm)-21.25M
Shares Out16.19M
EPS (ttm)-1.43
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume28,916
Open3.75
Previous Close3.77
Day's Range3.67 - 3.75
52-Week Range3.66 - 47.86
Betan/a
Analystsn/a
Price Targetn/a
Earnings Daten/a

About SCPS

Scopus BioPharma Inc., a biopharmaceutical company, focuses on developing transformational therapeutics targeting serious diseases. Its lead development programs are immuno-oncology gene therapy for the treatment of various cancers, which include CO-sTiRNA, a STAT3 inhibitor gene therapy that drives tumor cell growth and anti-tumor immune suppression; and MRI-1867, a cannabinoid-1 receptor inverse agonist and inhibitor of inducible nitric oxide synthase for the treatment of systemic sclerosis. Scopus BioPharma Inc. has strategic partnerships wi...

IndustryBiotechnology
IPO DateDec 16, 2020
Employees1
Stock ExchangeNASDAQ
Ticker SymbolSCPS
Full Company Profile

Financial Performance

Financial Statements

News

Scopus BioPharma Announces Adjournment of Annual Meeting of Stockholders

NEW YORK, Oct. 08, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: “SCPS”), a clinical-stage biopharmaceutical company developing transformational therapeutics for serious diseases with signific...

2 weeks ago - GlobeNewsWire

Scopus BioPharma to Present at the LD Micro Main Event

Scopus to present on the recent launch of Duet Therapeutics,  its wholly-owned subsidiary focused on immuno-oncology

3 weeks ago - GlobeNewsWire

Scopus BioPharma Retaining Counsel to Investigate Unusual Market Activity

NEW YORK, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: “SCPS”), a clinical-stage biopharmaceutical company, announced today that it is retaining Boies Schiller Flexner LLP to conduct...

3 weeks ago - GlobeNewsWire

Scopus BioPharma to Present at MicroCap Rodeo's Fall Harvest Best Ideas Conference

Scopus to present on the recent launch of Duet Therapeutics,  its wholly-owned subsidiary focused on immuno-oncology

3 weeks ago - GlobeNewsWire

Scopus BioPharma's Subsidiary — Duet Therapeutics — Announces Release of Preclinical Data Being Presented at 17th Ann...

Data from two different studies benchmark Duet's proprietary bifunctional oligonucleotides against immune checkpoint inhibitors (“Checkpoint Inhibitors”) in lymphoma and prostate tumor models in mice

3 weeks ago - GlobeNewsWire

Scopus BioPharma's Subsidiary Duet Therapeutics Set to Release Scientific Data During the 17th Annual Meeting of the ...

Duet releases video depicting mechanism of action for its proprietary CpG-STAT3 inhibitors to coincide with Duet presentations at OTS Meeting Duet releases video depicting mechanism of action for its pr...

4 weeks ago - GlobeNewsWire

Scopus BioPharma's Subsidiary — Duet Therapeutics — Set to Release Scientific Data During the 17th Annual Meeting of ...

Duet releases video depicting mechanism of action for its proprietary CpG-STAT3 inhibitors to coincide with Duet presentations at OTS Meeting Duet releases video depicting mechanism of action for its pr...

4 weeks ago - GlobeNewsWire

Scopus BioPharma to Adjourn 2021 Annual Meeting of Stockholders

NEW YORK, Sept. 28, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: “SCPS”), a clinical-stage biopharmaceutical company developing transformational therapeutics for serious diseases with signifi...

4 weeks ago - GlobeNewsWire

Scopus BioPharma's Subsidiary — Duet Therapeutics — to Present at the 17th Annual Meeting of the Oligonucleotide Ther...

Alan Horsager, Ph.D., President and Chief Executive Officer of Duet Therapeutics, will present on CpG-STAT3 RNA Silencing and Antisense inhibitors

1 month ago - GlobeNewsWire

China National Intellectual Property Administration Grants New Patent Covering DUET-02, One of Three Key CpG-STAT3 In...

New patent covers compound and composition and methods of use for CpG-STAT3 Antisense inhibitor (CpG-STAT3ASO)

1 month ago - GlobeNewsWire

Dr. Morris C. Laster Files Preliminary Proxy Statement Nominating Two Highly-Qualified Individuals For Election To Bo...

JERUSALEM, Sept. 20, 2021 /PRNewswire/ -- Dr. Morris C.

Other symbols:XTLB
1 month ago - PRNewsWire

Scopus BioPharma's Subsidiary — Duet Therapeutics — Announces Appointment of Marcin Kortylewski, Ph.D. as Senior Scie...

Dr. Kortylewski is the Leading Authority on Bi-Functional Oligonucleotide Cancer Therapeutics and a Professor in the Department of Immuno-Oncology at the Beckman Research Institute at City of Hope Natio...

1 month ago - GlobeNewsWire

Scopus BioPharma's Subsidiary — Duet Therapeutics — to Present at the 14th Annual RNA Consortium Meeting

Alan Horsager, Ph.D., President and Chief Executive Officer of Duet, to Present on Clinical Development of CpG-STAT3 Inhibitors Alan Horsager, Ph.D., President and Chief Executive Officer of Duet, to Pr...

1 month ago - GlobeNewsWire

What Is Happening With Scopus BioPharma Stock On Thursday?

Scopus BioPharma Inc (NASDAQ: SCPS) has launched Duet Therapeutics that integrates the management and clinical development of the immunotherapy assets of Scopus and Olimmune. Related Content: Scopus Bio...

1 month ago - Benzinga

Scopus BioPharma Launches Duet Therapeutics

Duet Therapeutics Integrates Immunotherapy Assets of Scopus and Olimmune, Acquired by Scopus in June 2021

1 month ago - GlobeNewsWire

5 Best Penny Stocks To Buy Right Now According To Insiders

5 Penny Stocks Insiders Are Buying Right Now The post 5 Best Penny Stocks To Buy Right Now According To Insiders appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Other symbols:ALTOCOCPEYENHOFV
2 months ago - PennyStocks

Scopus BioPharma Announces New Management Appointment Following Acquisition of Leading Immunotherapy Company

NEW YORK, July 12, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: “SCPS”), a clinical-stage biopharmaceutical company developing transformational therapeutics for serious diseases with signific...

3 months ago - GlobeNewsWire

Scopus BioPharma Expands Immunotherapy Pipeline with Acquisition of Olimmune

Transaction Creates Global Leader in Oligonucleotide Cancer Therapeutics

3 months ago - GlobeNewsWire

Scopus BioPharma Announces New Date for 2021 Annual Meeting of Stockholders

NEW YORK, May 31, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: “SCPS”) today announced that the board of directors has rescheduled the company's 2021 Annual Meeting of Stockholders (“2021 Ann...

4 months ago - GlobeNewsWire

Scopus BioPharma to Reschedule 2021 Annual Meeting of Shareholders

NEW YORK, May 26, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: “SCPS”) today announced it will be rescheduling the company's 2021 Annual Meeting of Shareholders (the “2021 Annual Meeting”), w...

4 months ago - GlobeNewsWire

Why Scopus BioPharma's Stock Is Surging Today

Scopus BioPharma (NASDAQ:SCPS) shares are trading higher after the company announced the FDA has approved its IND application for CpG-STAT3siRNA, the company's distinctive immuno-oncology RNA therapy fo...

5 months ago - Benzinga

SCPS Stock: The Huge FDA News Sending Scopus BioPharma Up 100%

Today, investors in SCPS stock are seeing their investment more than double on a key announcement of an FDA approval for a core therapy. The post SCPS Stock: The Huge FDA News Sending Scopus BioPharma U...

5 months ago - InvestorPlace

Why Scopus, NGM Biopharma and Taiwan Liposome Are Moving Today

Scopus BioPharma Inc. (NASDAQ: SCPS), NGM Biopharmaceuticals, Inc. (NASDAQ: NGM) and Taiwan Liposome Company, Ltd. (NASDAQ: TLC) are among the biggest biopharma movers Monday.

Other symbols:NGMTLC
5 months ago - Benzinga

Why Scopus BioPharma Stock More Than Double Today?

The FDA has signed off investigational new drug application of Scopus BioPharma Inc's (NASDAQ: SCPS) for CpG-STAT3siRNA, the company's distinctive immuno-oncology RNA therapy for the treatment of multip...

5 months ago - Benzinga

Why Did Scopus BioPharma's Stock More Than Double Today?

The FDA has signed off investigational new drug application of Scopus BioPharma Inc's (NASDAQ: SCPS) for CpG-STAT3siRNA, the company's distinctive immuno-oncology RNA therapy for the treatment of multip...

5 months ago - Benzinga